<html>
<head>PUBMED IDs for YRDC</head>
<body bgcolor='#C5F0F2'><h1>YRDC</h1><a href='https://pubmed.ncbi.nlm.nih.gov/27904673/'>MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC.</a> December 3  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27904668/'>AGE/RAGE promotes thecalcification of human aortic smooth muscle cells via the Wnt/β-catenin axis.</a> December 3  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27904655/'>Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5'-monophosphate response element modulator alpha in systemic lupus erythematosus.</a> April 30  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27904654/'>Augmentation of histone deacetylase 3 (HDAC3) epigenetic signature at the interface of proinflammation and insulin resistance in patients with type 2 diabetes.</a> April 30  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27904617/'>The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.</a> December 3  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27904556/'>The effect of ω-fatty acids on the expression of phospholipase A2 group 2A in human gastric cancer patients.</a> December 3  2016<br></body></html>
